NCT03190239

Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed After First - Line Induction Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer: A Prospective, Open, Single Arm Clinical Study

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Xinqiao Hospital of Chongqing · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Lung cancer is a malignant tumor that causes the highest morbidity and mortality, and the main pathological type is non-small cell lung cancer (NSCLC). Most of them present with advanced stage at diagnosis. This design is to study maintenance therapy with pemetrexed plus apatinib after first line induction therapy four cycles for advanced non-squamous non-small-cell lung cancer. XQonc-0007

Detailed description

XQonc-0007

Conditions

• Advanced Non-squamous Non-small-cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Apatinib	Apatinib 250mg qd
DRUG	Pemetrexed	Pemetrexed 500mg/m2 qm

Timeline

• Start date: 2017-07-15
• Primary completion: 2020-07-30
• Completion: 2020-07-30
• First posted: 2017-06-16
• Last updated: 2024-02-28

Locations

1 site across 1 country: China